FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225291877> ?p ?o ?g. }

• W4225291877 endingPage "658" @default.
• W4225291877 startingPage "650" @default.
• W4225291877 abstract "BackgroundRecurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival in muscle-invasive bladder cancer.MethodsNEOBLADE was a parallel-arm, double-blind, randomised, placebo-controlled, phase 2 trial of neoadjuvant gemcitabine and cisplatin chemotherapy with nintedanib or placebo in locally advanced muscle-invasive bladder cancer. Patients aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0–1, were recruited from 15 hospitals in the UK. Patients were randomly assigned (1:1) to nintedanib or placebo using permuted blocks with random block sizes of two or four, stratified by centre and glomerular filtration rate. Treatments were allocated using an interactive web-based system, and patients and investigators were masked to treatment allocation throughout the study. Patients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m2 on days 1 and 8 and intravenous cisplatin 70 mg/m2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or at day 8 of cyclde 3 (plus or minus 7 days) if cystectomy did not occur. Primary analyses were done in the intention-to-treat population. The trial is registered with EudraCT, 2012-004895-01, and ISRCTN, 56349930, and has completed planned recruitment.FindingsBetween Dec 4, 2014, and Sept 3, 2018, 120 patients were recruited and were randomly allocated to receive nintedanib (n=57) or placebo (n=63). The median follow-up for the study was 33·5 months (IQR 14·0–44·0). Pathological complete response in the intention-to-treat population was reached in 21 (37%) of 57 patients in the nintedanib group and 20 (32%) of 63 in the placebo group (odds ratio [OR] 1·25, 70% CI 0·84–1·87; p=0·28). Grade 3 or worse toxicities were observed in 53 (93%) of 57 participants who received nintedanib and 50 (79%) of 63 patients in the placebo group (OR 1·65, 95% CI 0·74–3·65; p=0·24). The most common grade 3 or worse adverse events were thromboembolic events (17 [30%] of 57 patients in the nintedanib group vs 13 [21%] of 63 patients in the placebo group [OR 1·63, 95% CI 0·71–3·76; p=0·29]) and decreased neutrophil count (22 [39%] in the nintedanib group vs seven [11%] in the placebo group [5·03, 1·95–13·00; p=0·0006]). 45 treatment-related serious adverse events occurred in the nintedanib group and 43 occurred in the placebo group. One treatment-related death occurred in the placebo group, which was due to myocardial infarction.InterpretationThe addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer.FundingBoehringer Ingelheim." @default.
• W4225291877 created "2022-05-05" @default.
• W4225291877 creator A5011126206 @default.
• W4225291877 creator A5012800133 @default.
• W4225291877 creator A5018306647 @default.
• W4225291877 creator A5022378006 @default.
• W4225291877 creator A5029515513 @default.
• W4225291877 creator A5029987103 @default.
• W4225291877 creator A5031306593 @default.
• W4225291877 creator A5032231578 @default.
• W4225291877 creator A5047234703 @default.
• W4225291877 creator A5048796030 @default.
• W4225291877 creator A5054724709 @default.
• W4225291877 creator A5060398342 @default.
• W4225291877 creator A5064442357 @default.
• W4225291877 creator A5066701655 @default.
• W4225291877 creator A5067448632 @default.
• W4225291877 creator A5073038301 @default.
• W4225291877 creator A5075388907 @default.
• W4225291877 creator A5078099654 @default.
• W4225291877 creator A5079820994 @default.
• W4225291877 creator A5087437906 @default.
• W4225291877 date "2022-05-01" @default.
• W4225291877 modified "2023-10-06" @default.
• W4225291877 title "Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial" @default.
• W4225291877 cites W1483015025 @default.
• W4225291877 cites W1550111394 @default.
• W4225291877 cites W1964037817 @default.
• W4225291877 cites W1973447263 @default.
• W4225291877 cites W1975918912 @default.
• W4225291877 cites W2047139557 @default.
• W4225291877 cites W2103561213 @default.
• W4225291877 cites W2136032744 @default.
• W4225291877 cites W2142173484 @default.
• W4225291877 cites W2146544748 @default.
• W4225291877 cites W2156845957 @default.
• W4225291877 cites W2164361265 @default.
• W4225291877 cites W2166453367 @default.
• W4225291877 cites W2170030318 @default.
• W4225291877 cites W2332342311 @default.
• W4225291877 cites W2544627141 @default.
• W4225291877 cites W2754362158 @default.
• W4225291877 cites W2755607580 @default.
• W4225291877 cites W2789871628 @default.
• W4225291877 cites W2793475328 @default.
• W4225291877 cites W2982865643 @default.
• W4225291877 cites W2990627920 @default.
• W4225291877 cites W3112930560 @default.
• W4225291877 cites W3113334560 @default.
• W4225291877 cites W3160424304 @default.
• W4225291877 doi "https://doi.org/10.1016/s1470-2045(22)00158-9" @default.
• W4225291877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35421369" @default.
• W4225291877 hasPublicationYear "2022" @default.
• W4225291877 type Work @default.
• W4225291877 citedByCount "7" @default.
• W4225291877 countsByYear W42252918772022 @default.
• W4225291877 countsByYear W42252918772023 @default.
• W4225291877 crossrefType "journal-article" @default.
• W4225291877 hasAuthorship W4225291877A5011126206 @default.
• W4225291877 hasAuthorship W4225291877A5012800133 @default.
• W4225291877 hasAuthorship W4225291877A5018306647 @default.
• W4225291877 hasAuthorship W4225291877A5022378006 @default.
• W4225291877 hasAuthorship W4225291877A5029515513 @default.
• W4225291877 hasAuthorship W4225291877A5029987103 @default.
• W4225291877 hasAuthorship W4225291877A5031306593 @default.
• W4225291877 hasAuthorship W4225291877A5032231578 @default.
• W4225291877 hasAuthorship W4225291877A5047234703 @default.
• W4225291877 hasAuthorship W4225291877A5048796030 @default.
• W4225291877 hasAuthorship W4225291877A5054724709 @default.
• W4225291877 hasAuthorship W4225291877A5060398342 @default.
• W4225291877 hasAuthorship W4225291877A5064442357 @default.
• W4225291877 hasAuthorship W4225291877A5066701655 @default.
• W4225291877 hasAuthorship W4225291877A5067448632 @default.
• W4225291877 hasAuthorship W4225291877A5073038301 @default.
• W4225291877 hasAuthorship W4225291877A5075388907 @default.
• W4225291877 hasAuthorship W4225291877A5078099654 @default.
• W4225291877 hasAuthorship W4225291877A5079820994 @default.
• W4225291877 hasAuthorship W4225291877A5087437906 @default.
• W4225291877 hasBestOaLocation W42252918771 @default.
• W4225291877 hasConcept C121608353 @default.
• W4225291877 hasConcept C126322002 @default.
• W4225291877 hasConcept C126894567 @default.
• W4225291877 hasConcept C141071460 @default.
• W4225291877 hasConcept C142724271 @default.
• W4225291877 hasConcept C143998085 @default.
• W4225291877 hasConcept C203092338 @default.
• W4225291877 hasConcept C204787440 @default.
• W4225291877 hasConcept C27081682 @default.
• W4225291877 hasConcept C2775910329 @default.
• W4225291877 hasConcept C2776694085 @default.
• W4225291877 hasConcept C2777714996 @default.
• W4225291877 hasConcept C2778292576 @default.
• W4225291877 hasConcept C2778341716 @default.
• W4225291877 hasConcept C2780171596 @default.
• W4225291877 hasConcept C2780258809 @default.
• W4225291877 hasConcept C2780352672 @default.
• W4225291877 hasConcept C2908647359 @default.
• W4225291877 hasConcept C530470458 @default.

• next